Opinion: Experimental medical devices should be made available to patients

Patients should have the option to take more risks when seeking medical treatment, said Dr. Kevin Tracey in a Wall Street Journal column. Tracey, a neurosurgeon and CEO of the Feinstein Institute for Medical Research, argued that the FDA should not be solely responsible for approving potentially lifesaving treatments because existing institutional review boards and protocols already protect against many unsafe procedures. Ultimately, he said, the patient's satisfaction should determine success of a treatment option. Strict government regulations are a deterrent for entrepreneurs such as Sergey Brin and Larry Page of Google ($GOOG), who recently commented that healthcare was "a painful business to be in" when asked if they would consider entering the field, Tracey said. Post (sub. req.)

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.